启动持续葡萄糖监测与1型和2型糖尿病患者的血糖控制改善及临床事件减少相关:退伍军人健康管理局研究
该回顾性观察性队列研究在退伍军人事务医疗系统内,比较启动持续葡萄糖监测(CGM)者与未使用者12个月内的血糖控制及低血糖或高血糖相关急诊就诊或住院和全因住院情况。结果显示CGM使用者糖化血红蛋白(HbA1c)下降更显著,且1型糖尿病低血糖和全因住院风险降低,2型糖尿病高血糖和全因住院风险降低。
要点
- 1型糖尿病CGM使用者12个月HbA1c降幅较非使用者大0.26%。
- 2型糖尿病CGM使用者12个月HbA1c降幅较非使用者大0.35%。
- 1型糖尿病CGM使用者低血糖住院风险HR 0.69,全因住院风险HR 0.75。
核心结论
- 在大型全国队列中,启动CGM与晚发型1型糖尿病及使用胰岛素的2型糖尿病患者HbA1c持续改善相关。
- 该改善伴随低血糖或高血糖相关急诊就诊或住院及全因住院风险降低的明确模式。
研究设计与样本
- 采用退伍军人事务医疗系统内的回顾性观察性队列研究。
- 比较倾向评分重叠加权后CGM启动者与未使用者12个月内的血糖控制及临床事件。
- 从2015年1月1日至2020年12月31日识别CGM使用者中接受胰岛素治疗者(1型糖尿病n=5,015,2型糖尿病n=15,706)及相似数量的非使用者。
主要发现
- 12个月时,1型糖尿病CGM使用者HbA1c降幅为-0.26%(95%CI -0.33, -0.19%),2型糖尿病CGM使用者为-0.35%(95%CI -0.40, -0.31%),均显著大于非使用者。
- 12个月后达到HbA1c<8%和<9%的患者比例在CGM使用者中更高。
- 1型糖尿病中,启动CGM与低血糖风险显著降低(HR 0.69;95%CI 0.48, 0.98)和全因住院风险显著降低(HR 0.75;95%CI 0.63, 0.90)相关。
- 2型糖尿病中,CGM使用者高血糖风险降低(HR 0.87;95%CI 0.77, 0.99)和全因住院风险降低(HR 0.89;95%CI 0.83, 0.97)。
- 若干亚组(基于基线年龄、HbA1c、低血糖风险或随访CGM使用)反应甚至更大。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the benefit of starting continuous glucose monitoring (CGM) in adult-onset type 1 diabetes (T1D) and type 2 diabetes (T2D) with regard to longer-term glucose control and serious clinical events. RESEARCH DESIGN AND METHODS: A retrospective observational cohort study within the Veterans Affairs Health Care System was used to compare glucose control and hypoglycemia- or hyperglycemia-related admission to an emergency room or hospital and all-cause hospitalization between propensity score overlap weighted initiators of CGM and nonusers over 12 months. RESULTS: CGM users receiving insulin (n = 5,015 with T1D and n = 15,706 with T2D) and similar numbers of nonusers were identified from 1 January 2015 to 31 December 2020. Declines in HbA1c were significantly greater in CGM users with T1D (-0.26%; 95% CI -0.33, -0.19%) and T2D (-0.35%; 95% CI -0.40, -0.31%) than in nonusers at 12 months. Percentages of patients achieving HbA1c <8 and <9% after 12 months were greater in CGM users. In T1D, CGM initiation was associated with significantly reduced risk of hypoglycemia (hazard ratio [HR] 0.69; 95% CI 0.48, 0.98) and all-cause hospitalization (HR 0.75; 95% CI 0.63, 0.90). In patients with T2D, there was a reduction in risk of hyperglycemia in CGM users (HR 0.87; 95% CI 0.77, 0.99) and all-cause hospitalization (HR 0.89; 95% CI 0.83, 0.97). Several subgroups (based on baseline age, HbA1c, hypoglycemic risk, or follow-up CGM use) had even greater responses. CONCLUSIONS: In a large national cohort, initiation of CGM was associated with sustained improvement in HbA1c in patients with later-onset T1D and patients with T2D using insulin. This was accompanied by a clear pattern of reduced risk of admission to an emergency room or hospital for hypoglycemia or hyperglycemia and of all-cause hospitalization.
引用
- Reaven PD, Newell M, Rivas S, et al. Initiation of Continuous Glucose Monitoring Is Linked to Improved Glycemic Control and Fewer Clinical Events in Type 1 and Type 2 Diabetes in the Veterans Health Administration. Diabetes Care. 2023. PMID: 36807492. doi:10.2337/dc22-2189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。